Apollomics Inc. Warrant
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, … Read more
Apollomics Inc. Warrant (APLMW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.384x
Based on the latest financial reports, Apollomics Inc. Warrant (APLMW) has a cash flow conversion efficiency ratio of -0.384x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.99 Million) by net assets ($20.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Apollomics Inc. Warrant - Cash Flow Conversion Efficiency Trend (2020–2023)
This chart illustrates how Apollomics Inc. Warrant's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Apollomics Inc. Warrant Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apollomics Inc. Warrant ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SURNF
OTCQB:SURNF
|
-0.058x |
|
Anglo Philippine Holdings Corp
PSE:APO
|
0.013x |
|
SCOA NIGERIA PLC
XNSA:SCOA
|
N/A |
|
Red Capital PLC
LSE:REDC
|
-1.970x |
|
Institute of Biomedical Research Corp
PINK:MRES
|
0.880x |
|
Synergia Energy Ltd.
LSE:SYN
|
-0.044x |
|
CWG PLC
XNSA:CWG
|
N/A |
|
DIH Holdings US, Inc. Class A Common Stock
NASDAQ:DHAI
|
0.089x |
Annual Cash Flow Conversion Efficiency for Apollomics Inc. Warrant (2020–2023)
The table below shows the annual cash flow conversion efficiency of Apollomics Inc. Warrant from 2020 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $41.23 Million | $-43.21 Million | -1.048x | -1196.54% |
| 2022-12-31 | $-448.12 Million | $-42.82 Million | 0.096x | -53.03% |
| 2021-12-31 | $-212.86 Million | $-43.31 Million | 0.203x | -27.04% |
| 2020-12-31 | $-127.93 Million | $-35.68 Million | 0.279x | -- |